Jonsson Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.cancer.ucla.edu

Clinical Trials

Near-Infrared Image Guided Surgical Resection With Indocyanine Green in Treating Patients With Head and Neck Cancer

Phase 1

Withdrawn

Conditions: Head and Neck Carcinoma

Interventions: Procedure: Image-Guided Surgery
Drug: Indocyanine Green Drug

First Posted Date: 2018-11-19

Last Posted Date: 2022-03-17

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT03745690

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer

Phase 2

Active, not recruiting

Conditions: Recurrent Fallopian Tube Carcinoma
Recurrent Primary Peritoneal Carcinoma
Recurrent Ovarian Carcinoma

Interventions: Biological: Pembrolizumab

First Posted Date: 2018-11-07

Last Posted Date: 2024-04-15

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 5

Registration Number: NCT03732950

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma

Phase 2

Completed

Conditions: EGFR Gene Amplification
EGFR Gene Mutation
Glioblastoma
Recurrent Glioblastoma
Supratentorial Glioblastoma
TP53 Wt Allele

Interventions: Other: Fludeoxyglucose F-18
Drug: Osimertinib
Procedure: Positron Emission Tomography

First Posted Date: 2018-11-06

Last Posted Date: 2024-11-12

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 12

Registration Number: NCT03732352

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer

Phase 2

Recruiting

Conditions: Recurrent Extensive Stage Small Cell Lung Carcinoma
Refractory Extensive Stage Small Cell Lung Carcinoma

Interventions: Drug: Talazoparib
Drug: Temozolomide

First Posted Date: 2018-09-14

Last Posted Date: 2024-11-05

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 28

Registration Number: NCT03672773

Locations: 🇺🇸
Ft. Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, United States
🇺🇸
St. Joseph Heritage Healthcare, Fullerton, California, United States
🇺🇸
CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center, Bakersfield, California, United States

and more 3 locations

Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma

Phase 2

Completed

Conditions: Metastatic Chordoma
Unresectable Chordoma
Chordoma
Locally Advanced Chordoma

Interventions: Biological: Nivolumab
Biological: Relatlimab

First Posted Date: 2018-08-09

Last Posted Date: 2024-04-16

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 10

Registration Number: NCT03623854

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner

Phase 1

Terminated

Conditions: p16 Positive Neoplastic Cells Present
Human Papillomavirus Positive
Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Oropharyngeal Squamous Cell Carcinoma
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC (American Joint Committee on Cancer) v8
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

Interventions: Biological: Durvalumab
Procedure: Modified Radical Neck Dissection
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Radiation: Stereotactic Body Radiation Therapy
Procedure: Transoral Robotic Surgery
Biological: Tremelimumab

First Posted Date: 2018-08-07

Last Posted Date: 2023-11-18

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 19

Registration Number: NCT03618134

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Pembrolizumab in Treating Participants with Leukoplakia

Phase 2

Recruiting

Conditions: Leukoplakia
Erythroleukoplakia
Verrucous Oral Leukoplakia

Interventions: Biological: Pembrolizumab

First Posted Date: 2018-07-27

Last Posted Date: 2024-10-17

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 26

Registration Number: NCT03603223

Locations: 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer

Phase 2

Active, not recruiting

Conditions: Bladder Urothelial Carcinoma
Stage IV Bladder Cancer AJCC v8
Stage IVA Bladder Cancer AJCC v8
Stage IVB Bladder Cancer AJCC v8

Interventions: Biological: Durvalumab
Radiation: External Beam Radiation Therapy
Biological: Tremelimumab

First Posted Date: 2018-07-26

Last Posted Date: 2024-03-07

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 13

Registration Number: NCT03601455

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Image-Guided Biopsies in Identifying Mechanisms of Resistance in Participants With Metastatic Castration Resistant Prostate Cancer Undergoing Radioligand Therapy

Not Applicable

Withdrawn

Conditions: Castration-Resistant Prostate Carcinoma
Metastatic Prostate Carcinoma
Stage IV Prostate Cancer

Interventions: Procedure: Image Guided Biopsy

First Posted Date: 2018-07-24

Last Posted Date: 2020-07-23

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT03596710

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

Phase 1

Completed

Conditions: Bladder Small Cell Neuroendocrine Carcinoma
Castration-Resistant Prostate Carcinoma
Metastatic Bladder Urothelial Carcinoma
Metastatic Urethral Urothelial Carcinoma
Prostate Carcinoma Metastatic in the Bone
Prostate Neuroendocrine Neoplasm
Prostate Small Cell Carcinoma
Stage III Bladder Cancer AJCC V8
Stage III Prostate Cancer AJCC V8
Stage III Urethral Cancer AJCC V8

Interventions: Drug: Carboplatin
Drug: Cisplatin
Drug: Docetaxel
Drug: Etoposide
Biological: Pembrolizumab

First Posted Date: 2018-07-11

Last Posted Date: 2023-04-12

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 15

Registration Number: NCT03582475

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy